Study to improve outcomes in osteosarcoma care through collaboration
Part of Cancer clinical trials.
This trial focuses on improving how osteosarcoma care is coordinated and delivered, using collaboration between clinicians. It may help by helping teams make more consistent treatment decisions for people newly diagnosed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a new diagnosis of osteosarcoma (bone cancer) confirmed by pathology/biopsy and scan findings
- If osteoid (a specific bone tissue finding) isn’t seen, your overall test results still strongly suggest osteosarcoma
- The diagnosis should be no more than 4 months before you register
- You (or your parent/legal guardian) can provide written consent to join the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at the experiences of people with osteosarcoma who are taking part in clinical trials. By joining, you'll help researchers understand what it's like for patients, which may improve future care.
This trial combines four targeted drugs (gefitinib, trametinib, disulfiram, sunitinib) with standard chemotherapy to treat osteosarcoma that has spread or come back. The goal is to see if this drug mix helps shrink tumors or keep them from growing.
This trial uses a lab-grown mini tumor (organoid) from your biopsy to test which drugs might work best for your osteosarcoma. It aims to personalize your treatment based on how your specific cancer cells respond.
This trial tests a combination of two drugs, losartan and sunitinib, in people with osteosarcoma that has come back or spread after prior treatment. The study aims to see if this combination is safe and effective.
This trial tests a new drug called OMO-103, which targets a protein called Myc that helps cancer cells grow. It is for people with advanced osteosarcoma (bone cancer) that has worsened after standard chemotherapy. The drug is given intravenously (through a vein), and the study will check if it is safe and shrinks tumors.
This study tests two treatments for high-risk osteosarcoma (a bone cancer). It compares mifamurtide plus standard treatment versus sorafenib plus standard treatment to see which is safer and more effective.
Hear when a new Osteosarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.